Symbiosis Pharmaceutical Services has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland. This advancement signifies a critical enhancement in Symbiosis’s manufacturing capabilities, addressing the increasing demand for high-quality sterile production in the biopharmaceutical sector.
The fully integrated sterile liquid fill/finish system operates under a Grade A Restricted Access Barrier System (RABS), ensuring precision and efficiency through advanced aseptic handling and high-accuracy vial filling. With features such as rapid transfer ports and a rotary crimp mechanism, the system guarantees consistent overseal application and secure closure, thereby meeting stringent regulatory standards.
Colin MacKay, CEO of Symbiosis, highlighted that this qualification is a major milestone that not only boosts their technical capabilities but also positions them to better support clients in delivering essential therapies to patients. The facility is set to commence commercial production in Q4 2025, with capabilities to manufacture batches of up to 15,000 vials, further solidifying Symbiosis’s role in the global biopharmaceutical supply chain.
This expansion follows a series of significant achievements for Symbiosis, including the production of its 1,000th sterile batch and recognition with the UK 2025 King’s Award for Enterprise in International Trade. With a proven track record of successful GMP inspections and a commitment to regulatory compliance, Symbiosis continues to establish itself as a trusted partner for biotechnology and pharmaceutical companies worldwide.
For more information on Symbiosis, visit http://www.symbiosis-pharma.com or follow them on LinkedIn.
Get started today with Solo access →
